Developer docs
API playgroundTry for free, no card

Search company profiles

Amorchem

Full company profile

uuid0002qui

Namestring
Amorchem
Websiteurl
amorchem.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Amorchem is a Montreal, Canada-based venture capital fund founded in 2011 that focuses on creating and backing promising life science companies. The firm operates with a small team of 1-10 employees, consistent with a specialist life sciences venture model where investment selection relies on deep domain expertise and active company-creation rather than high-volume deal flow.

The fund's core activity is sourcing, building, and financing early-stage life science ventures in the Quebec/Canadian ecosystem. Its business model follows the standard venture fund structure: it raises capital from limited partners, deploys that capital into portfolio companies, and earns returns through a combination of management fees on assets under management and carried interest on successful exits. In November 2018, the firm secured a $50,000,000 financing round with VCCI as lead investor, providing material dry powder for continued investment activity. The leadership team includes Founder & Partner Elizabeth Douville and CFO & Partner Maxime Pesant, whose domain and financial roles anchor fund operations.

No specific portfolio companies, AUM growth, performance metrics, or recent transaction activity are disclosed in the available input material, limiting forward visibility into investment pacing, exit realization, or fee revenue trends beyond the inferred management-fee economics on the single observed fund close.

Short descriptiontext

Amorchem is a Montreal-based venture capital fund founded in 2011 that creates and invests in early-stage life science companies, operating with a small specialized team of 1-10 employees.

Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWestmount, Canada
HQ citystring
Westmount
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
venture capital, life sciences investment, biotech funding, early-stage pharma, healthcare venture
Industry1 code
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
NAICS code1 code
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Life Sciences Venture Capital
Social media profiles1 record
Cost components3 values
Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Amorchem is a venture capital fund that invests in and builds early-stage life sciences companies. The firm deploys committed capital into biotech, pharmaceutical, and medical-technology ventures primarily sourced from the Montreal research ecosystem. It operates as a hands-on, founder-led investment partner, providing both capital and operational support to portfolio companies from inception through value-inflection milestones.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Amorchem Life Sciences Venture Fund
CategoryVenture capital fund management
Description

Venture capital fund (with a CAD $50M commitment from the Venture Capital Catalyst Initiative raised on 2018-11-05) that invests in early-stage life sciences companies, providing capital, operating support, and partner-led company-building to biotech and health-technology ventures.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canadian healthcare and life-sciences venture capital firm investing across biotech and digital health; highly comparable to Amorchem in mandate, regional presence, and fund size.

TypeDirect peer
Description

Toronto-based Canadian life-sciences venture capital firm that builds and backs emerging health companies; directly comparable to Amorchem in sector focus and early-stage strategy.

TypeBroad incumbent
Description

Large, established North American healthcare and biotech venture capital firm; comparable sector focus but materially larger fund sizes and broader stage remit than Amorchem.

TypeBroad incumbent
Description

Global healthcare-dedicated investment firm spanning venture, growth, credit, and public equities; comparable life-sciences focus but operates at vastly greater scale than Amorchem.

TypeDirect peer
Description

Montreal-based life-sciences venture capital firm focused on early-stage therapeutics; closely comparable to Amorchem in geography, sector focus (Canadian biotech), and company-creation thesis.

TypeBroad incumbent
Description

US-based life-sciences-focused venture capital firm investing across biopharma; comparable in vertical specialization but with larger capital bases than Amorchem.

TypeBroad incumbent
Description

Translational biotech venture firm originally linked to GSK, investing in early-stage therapeutics and platforms; comparable specialization but corporate CVC-style backing contrasts with Amorchem's independent model.

TypeEmerging player
Description

US biotech early-stage venture firm focused on company creation from academic science; comparable founding thesis to Amorchem in building companies from research-stage assets.

TypeBroad incumbent
Description

Healthcare-focused growth and venture capital firm investing across biotech and medical devices; comparable vertical scope to Amorchem but with later-stage bias.

TypeRegional player
Description

Canadian Crown corporation venture arm with a dedicated healthcare/life-sciences fund supporting early-stage Quebec and Canadian biotech; comparable regional footprint and stage focus to Amorchem.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks10 records

Each record includes

Headline, Details, Source

Key highlights10 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment7 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Amorchem

Life Sciences Venture Capitalamorchem.com

Amorchem is a Montreal-based venture capital fund founded in 2011 that creates and invests in early-stage life science companies, operating with a small specialized team of 1-10 employees.

What Amorchem does

Amorchem is a Montreal, Canada-based venture capital fund founded in 2011 that focuses on creating and backing promising life science companies. The firm operates with a small team of 1-10 employees, consistent with a specialist life sciences venture model where investment selection relies on deep domain expertise and active company-creation rather than high-volume deal flow.

The fund's core activity is sourcing, building, and financing early-stage life science ventures in the Quebec/Canadian ecosystem. Its business model follows the standard venture fund structure: it raises capital from limited partners, deploys that capital into portfolio companies, and earns returns through a combination of management fees on assets under management and carried interest on successful exits. In November 2018, the firm secured a $50,000,000 financing round with VCCI as lead investor, providing material dry powder for continued investment activity. The leadership team includes Founder & Partner Elizabeth Douville and CFO & Partner Maxime Pesant, whose domain and financial roles anchor fund operations.

No specific portfolio companies, AUM growth, performance metrics, or recent transaction activity are disclosed in the available input material, limiting forward visibility into investment pacing, exit realization, or fee revenue trends beyond the inferred management-fee economics on the single observed fund close.

Amorchem firmographics

Firmographics
Name
Amorchem
Website
https://amorchem.com
Company type
Private
Founded year
2011
Headcount range
1–10 employees
Short description
Amorchem is a Montreal-based venture capital fund founded in 2011 that creates and invests in early-stage life science companies, operating with a small specialized team of 1-10 employees.
Ownership category
akta.pro rank

Amorchem industry classification

Industry
Product category
Life Sciences Venture Capital
NAICS
Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)

Keywords

  • Venture capital
  • Life sciences investment
  • Biotech funding
  • Early-stage pharma
  • Healthcare venture

Where Amorchem is headquartered

Location

Headquarters

HQ city
Westmount
HQ country
Canada
HQ region
North America

Markets served

Amorchem business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Others

Amorchem product offering

Product offering

Core offering

Amorchem is a venture capital fund that invests in and builds early-stage life sciences companies. The firm deploys committed capital into biotech, pharmaceutical, and medical-technology ventures primarily sourced from the Montreal research ecosystem. It operates as a hands-on, founder-led investment partner, providing both capital and operational support to portfolio companies from inception through value-inflection milestones.

Differentiator

Problem solved

Functional benefit

Products and services

  • Amorchem Life Sciences Venture Fund Venture capital fund (with a CAD $50M commitment from the Venture Capital Catalyst Initiative raised on 2018-11-05) that invests in early-stage life sciences companies, providing capital, operating support, and partner-led company-building to biotech and health-technology ventures.

Companies that use Amorchem

Customer profile

Ideal customer profiles2 records

Amorchem technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Amorchem partnerships and signals

Strategic signal

Recent moves2 records

Expansion highlights2 records

Amorchem competitors and assessment

Company assessment

Direct peers

  • Lumira Ventures: Canadian healthcare and life-sciences venture capital firm investing across biotech and digital health; highly comparable to Amorchem in mandate, regional presence, and fund size.
  • Genesys Capital: Toronto-based Canadian life-sciences venture capital firm that builds and backs emerging health companies; directly comparable to Amorchem in sector focus and early-stage strategy.
  • TVM Life Science Ventures: Montreal-based life-sciences venture capital firm focused on early-stage therapeutics; closely comparable to Amorchem in geography, sector focus (Canadian biotech), and company-creation thesis.

Broad incumbents

  • Versant Ventures: Large, established North American healthcare and biotech venture capital firm; comparable sector focus but materially larger fund sizes and broader stage remit than Amorchem.
  • OrbiMed Advisors: Global healthcare-dedicated investment firm spanning venture, growth, credit, and public equities; comparable life-sciences focus but operates at vastly greater scale than Amorchem.
  • Frazier Life Sciences: US-based life-sciences-focused venture capital firm investing across biopharma; comparable in vertical specialization but with larger capital bases than Amorchem.
  • SR One (GSK): Translational biotech venture firm originally linked to GSK, investing in early-stage therapeutics and platforms; comparable specialization but corporate CVC-style backing contrasts with Amorchem's independent model.
  • Domain Associates: Healthcare-focused growth and venture capital firm investing across biotech and medical devices; comparable vertical scope to Amorchem but with later-stage bias.

Emerging players

  • 5AM Ventures: US biotech early-stage venture firm focused on company creation from academic science; comparable founding thesis to Amorchem in building companies from research-stage assets.

Regional players

  • BDC Capital (Health Venture): Canadian Crown corporation venture arm with a dedicated healthcare/life-sciences fund supporting early-stage Quebec and Canadian biotech; comparable regional footprint and stage focus to Amorchem.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks10 records

Key highlights10 records

Customer concentration

Amorchem social profiles

Digital presence

Amorchem financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Amorchem leadership team

Management profile

Number of profiles

Profiles2 records

Amorchem funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Amorchem M&A and investment

M&A and investment

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amorchem

What does Amorchem do?

Amorchem is a venture capital fund that invests in and builds early-stage life sciences companies. The firm deploys committed capital into biotech, pharmaceutical, and medical-technology ventures primarily sourced from the Montreal research ecosystem. It operates as a hands-on, founder-led investment partner, providing both capital and operational support to portfolio companies from inception through value-inflection milestones.

When was Amorchem founded?

Amorchem was founded in 2011. It employs 1 to 10 people.

Where is Amorchem based?

Amorchem is headquartered in Westmount, Canada, in the North America region.

Who are Amorchem's main competitors?

Direct peers on record are Lumira Ventures, Genesys Capital and TVM Life Science Ventures. Broad incumbents are Versant Ventures, OrbiMed Advisors, Frazier Life Sciences, SR One (GSK) and Domain Associates. 5AM Ventures is listed as an emerging player. BDC Capital (Health Venture) is listed as a regional player.

Does Amorchem have an API?

No public API is recorded for Amorchem.

What industry is Amorchem in?

Amorchem's product category is Life Sciences Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsInversago Pharma Receives $7M in Series A FinancingInversago Pharma, a Montreal-based biotech, raised $7M in Series A financing co-led by Genesys Capital and Amorchem. The funds will advance its peripherally-restricted CB1 inverse agonist/antagonist program into clinical trials for Prader-Willi Syndrome, type 1 diabetes, and obesity.BetaKitAmorchem closes $44.2 million for biotech fundAmorChem closed a $44.2 million second fund to invest in seed-stage biotech companies. The fund was backed by the Québec government, Fonds de solidarité FTQ, Merck, and other investors. The company plans to collaborate with academic partners to build a portfolio of new opportunities.FinSMEsSpecificiT Raises Seed FinancingSpecificiT Pharma, a Montreal-based biopharmaceutical company, completed an undisclosed seed financing with backers including AmorChem, Sanderling Ventures, and Accel-Rx Health Sciences. The funds will support manufacturing, process development, and hiring, with Pierre Beauparlant appointed CEO. The company is developing cellular therapies for hematological cancers using Minor Histocompatibility Antigens.PR NewswireSpecificiT Raises Seed FinancingSpecificiT Pharma completed seed financing from AmorChem, Sanderling Ventures, and Accel-Rx. The funds will support manufacturing, process development, and hiring, with CEO Pierre Beauparlant joining. The company is conducting a Phase I study on its MiHA-based donor T-cell therapy for hematological cancers.PR NewswireSpecificiT Raises Seed FinancingSpecificiT Pharma Inc., a Montreal-based biopharmaceutical company developing personalized hematological cancer immunotherapies, completed a seed financing round with investors AmorChem, Sanderling Ventures, and Accel-Rx. Pierre Beauparlant from Sanderling Ventures will assume the role of Chief Executive Officer, and proceeds will support manufacturing, process development, and management expansion. The company is currently conducting a multi-centre Phase I study for its therapy targeting hematological cancers, including Acute Myeloid Leukemia, with the goal of improving efficacy and reducing graft-versus-host disease side effects.FinSMEsAmorChem Receives $6.8M Investment from Merck CanadaAmorChem, a Quebec-based life sciences venture capital fund, received a $6.8M investment from Merck Canada. The fund will invest in early-stage therapeutic, diagnostic, and medical device projects and create opportunities for seven former Merck Canada employees. It aims to fund very early-stage projects to rapidly reap commercial benefits from Quebec's academic R&D.